Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected PersonsJune 15, 1998Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and AdolescentsAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-12_Part_2-199806151-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractThe availability of an increasing number of antiretroviral agents and the rapid evolution of new information has introduced extraordinary complexity into the treatment of HIV-infected persons. In 1996, the Department of Health and Human Services and the Henry J. Kaiser Family Foundation convened the Panel on Clinical Practices for the Treatment of HIV to develop guidelines for the clinical management of HIV-infected adults and adolescents.This report recommends that care should be supervised by an expert, and it makes recommendations for laboratory monitoring with particular emphasis on measurement of plasma levels of HIV RNA.It also provides guidelines for antiretroviral therapy, including when to start treatment, what drugs to initiate, when to change therapy, and therapeutic options when changing therapy. Special consideration is given to adolescents and pregnant women. As with decisions about treatment of other chronic conditions, therapeutic decisions about HIV disease require a mutual understanding between the patient and the health care provider regarding the benefits and risks of treatment. Like treatment for most chronic diseases, antiretroviral regimens are complex, have major side effects, pose difficulty with compliance, and carry serious potential consequences with the risk for resistance from nonadherence to the drug regimen or suboptimal levels of antiretroviral agents. Patient education and involvement in therapeutic decisions is important for all medical conditions but is considered especially critical for HIV infection and its treatment.With regard to specific recommendations, treatment should be offered to all patients with the acute HIV syndrome, those within 6 months of seroconversion, and all patients with symptoms ascribed to HIV infection.Recommendations for offering antiretroviral therapy to asymptomatic patients depend on virologic and immunologic factors. In general, treatment should be offered to individuals with fewer than 500 CD4+ T cells/mm3 or plasma HIV RNA levels exceeding 10 000 copies/mL (branched DNA assay) or 20 000 copies/mL (reverse transcriptase polymerase chain reaction assay). The strength of the recommendation to treat asymptomatic patients should be based on the patient's willingness to accept therapy, the probability of adherence with the prescribed regimen, and the prognosis in terms of time to an AIDS-defining complication as predicted by plasma HIV RNA levels and CD4+ T-cell counts, which independently help predict prognosis. Once the decision has been made to initiate antiretroviral therapy, the goal is maximum viral suppression for as long as possible. Results of clinical trials to date indicate that this may currently be best achieved with a potent protease inhibitor in combination with two nucleoside analogue reverse transcriptase inhibitors (NRTIs). Another option is the combination of saquinavir plus ritonavir combined with one or two NRTIs. Other currently available regimens may be used in selected settings but are considered by many to be less likely to produce maximum viral suppression. Results of therapy are evaluated primarily with plasma HIV RNA levels; these are expected to show a one-log (10-fold) decrease at 8 weeks and no detectable virus (<500 copies/mL) at 4 to 6 months after initiation of treatment. Failure of therapy (i.e., plasma HIV RNA levels >500 copies/mL) at 4 to 6 months may be ascribed to nonadherence, inadequate potency of drugs or suboptimal levels of antiretroviral agents, resistance, and other factors that are poorly understood. Patients whose therapy fails should change to at least two new agents that are not likely to show cross-resistance with drugs given previously; ideally, the regimen should be changed to a completely new regimen that is devoid of anticipated cross-resistance and for which clinical trial data support a high probability of viral response. Rational changes in therapy may be especially difficult to achieve for patients for whom the preferred regimen has failed, because of limitations in the available alternative antiretroviral regimens that have documented efficacy; these decisions are further confounded by problems with adherence, toxicity, and resistance. In some settings, it may be preferable for a patient to participate in a clinical trial with or without access to new drugs or to use a regimen that may not achieve the optimal virologic goal.It is emphasized that concepts relevant to HIV management evolve rapidly.The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the AIDS Treatment Information Service World Wide Web site (http://www.hivatis.org).These Guidelines were developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J.Kaiser Family Foundation. Leadership of the Panel consists of Anthony S. Fauci, National Institutes of Health, Bethesda, MD (co-chair); John G. Bartlett, Johns Hopkins University, Baltimore, MD (co-chair); Eric P. Goosby, Department of Health and Human Services (convener); Mark D. Smith, California HealthCare Foundation, San Francisco, CA, formerly of the Henry J. Kaiser Foundation (convener), succeeded by Sophia W. Chang, Henry J. Kaiser Foundation.Members of the Panel who participated in the development of this document included Jean Anderson (Johns Hopkins University, Baltimore, MD), Rodney Armstead (Watts Health Foundation, Inc., Inglewood, CA), A. Cornelius Baker (National Association of People with AIDS, Washington, DC), David Barr (Forum for Collaborative HIV Research, Washington, DC), Samuel Bozzette (San Diego Veterans Affairs Medical Center, San Diego, CA), Spencer Cox (Treatment Action Group, New York, NY), Martin Delaney (Project Inform, San Francisco, CA), Fred Gordin (Veterans Administration Medical Center, Washington, DC), Wayne Greaves (Howard University, Washington, DC), Mark Harrington (Treatment Action Group, New York, NY), John J. Henning (American Medical Association, Chicago, IL), Martin S. Hirsch (Massachusetts General Hospital, Boston, MA), Jeffrey Jacobs (AIDS Action Council), Richard Marlink (Harvard AIDS Institute, Cambridge, MA), Celia Maxwell (AIDS Education and Training Center, Washington, DC), John W. Mellors (University of Pittsburgh, Pittsburgh, PA), David B. Nash (Thomas Jefferson University, Philadelphia, PA), Sallie Perryman (New York State Department of Health, New York, NY), Robert T. Schooley (University of Colorado, Denver, CO), Renslow Sherer (Cook County HIV Primary Care Center, Chicago, IL), Stephen A. Spector (University of California San Diego, La Jolla, CA), Gabriel Torres (St. Vincent's Hospital, New York, NY), Paul Volberding (University of California, San Francisco, CA); participants from the Department of Health and Human Services: Barbara A. Brady (Office of HIV/AIDS Policy), Oren Cohen (National Institutes of Health), Elaine M. Daniels (Office of HIV/AIDS Policy), David Feigal (Food and Drug Administration), Mark Feinberg (National Institutes of Health), Helene D. Gayle (Centers for Disease Control and Prevention), T. Randolph Graydon (Health Care Financing Administration), Jonathan Kaplan (Centers for Disease Control and Prevention), Abe Macher (Health Resources and Services Administration), R. Frank Martin (Indian Health Service), Henry Masur (National Institutes of Health), Lynne Mofenson (National Institutes of Health), Jeffrey Murray (Food and Drug Administration), Joseph O'Neill (Health Resources and Services Administration), Lucille C. Perez (Substance Abuse and Mental Health Services Administration), Richard Riseberg (Office of the Secretary), Samuel Shekar (Health Care Financing Administration), Sharilyn K. Stanley (National Institutes of Health), Jack Whitescarver (Office of AIDS Research). The Panel would like to extend special appreciation to Charles Carpenter (Brown University School of Medicine, Providence, RI) for his advice in the development of this document and Gerry Bally (Health Canada) and Anita Rachlis (Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada) for their participation. The Panel would also like to acknowledge the special contributions of Sharilyn K. Stanley, Barbara A. Brady, and Elaine M. Daniels in the preparation of this document.References 1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1997; 46(RR-12):1-46. Google Scholar 2. Perelson A, Essunger Y, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997; 387:188-91. Google Scholar 3. Stein D, Korvick J, Vermund S. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992; 165:352-63. Google Scholar 4. Carpenter C, Fischl M, Hammer S, et al. Updated recommendations of the International AIDS Society Panel-USA Panel. JAMA. 1997; 277:1962-9. Google Scholar 5. Raboud J, Montaner J, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis. 1996; 174:191-4. Google Scholar 6. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992; 41(RR-17). Google Scholar 7. Fischl M, Richman D, Grieco M, et al. The efficacy of azidothymidine in the treatment of patients with AIDS and AIDS-related complex: a double blind, placebo controlled trial. N Engl J Med. 1987; 317:185-91. Google Scholar 8. Fischl M, Richman D, Hansen H, et al. The safety and efficacy of zidovudine in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 infection: a double blind, placebo controlled trial. Ann Intern Med. 1990; 112:727-37. Google Scholar 9. Volberding P, Lagakos S, Koch M, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990; 322:941-9. Google Scholar 10. Volberding P, Lagakos S, Grimes J, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994; 272:437-42. Google Scholar 11. Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996; 335:1081-90. Google Scholar 12. Mellors J, Munoz A, Giorgi J, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126:946-54. Google Scholar 13. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less. AIDS Clinical Trials Group 320 Study Section. N Engl J Med. 1997; 337:725-33. Google Scholar 14. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-9. Google Scholar 15. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996; 124:1019-30. Google Scholar 16. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA. 1998; 279:930-7. Google Scholar 17. Bartlett J. Protease inhibitors for HIV infection. Ann Intern Med. 1996; 124:1086-8. Google Scholar 18. Schapiro J, Winters M, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996; 124:1039-50. Google Scholar 19. Eron J, Benoit S, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995; 333:1662-9. Google Scholar 20. Staszewski S, Loveday C, Picazo J, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA. 1996; 276:111-7. Google Scholar 21. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995; 171:1411-9. Google Scholar 22. Keulen W, Back N, van Wijk A, et al. Initial appearance of the 184lle variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1997; 71:3346-50. Google Scholar 23. Dube M, Johnson D, Currier J, et al. Protease inhibitor-associated hyper-glycaemia [Letter]. Lancet. 1997; 350:713-4. Google Scholar 24. Visnegarwala F, Krause K, Musher D. Severe diabetes associated with protease inhibitor therapy [Letter]. Ann Intern Med. 1997; 127:947. Google Scholar 25. Eastone J, Decker C. New-onset diabetes mellitus associated with use of protease inhibitor [Letter]. Ann Intern Med. 1997; 127:948. Google Scholar 26. Clinical update-impact of HIV protease inhibitors on the treatment of HIV infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep. 1996; 45:921-5. Google Scholar 27. Niu M, Stein D, Schnittman S. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis. 1993; 168:1490-501. Google Scholar 28. Schacker T, Collier A, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125:257-64. Google Scholar 29. Kinloch-de Loes S, de Saussure P, Saurat J, et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 1993; 17:59-65. Google Scholar 30. Tindall B, Cooper D. Primary HIV infection: host responses and intervention strategies. AIDS. 1991; 5:1-14. Google Scholar 31. Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997; 175:1051-5. Google Scholar 32. Update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep. 1996; 45:468-80. Google Scholar 33. Hoen B, Harzic M, Fleury H, et al. ANRS053 trial of zidovudine, lamivudine, and ritonavir combination in patients with symptomatic primary HIV-1 infection: preliminary results [Abstract]. In: Proceedings of the Fourth Conference of Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997:107. Google Scholar 34. Tamalet C, Poizot Martin I, LaFeuillade A, et al. Viral load and genotypic resistance pattern in HIV-1 infected patients treated by a triple combination therapy including nucleoside and protease inhibitors initiated at primary infection [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC, 22-26 January, 1997:174. Google Scholar 35. Perrin L, Markowitz M, Calandra G, et al. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate [Abstract]. In Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997:108. Google Scholar 36. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997; 176:478-89. Google Scholar 37. Hanson C, Cooper E, Antonelli T, et al. Lack of tumors in infants with perinatal HIV exposure and fetal/neonatal exposure to zidovudine [Abstract]. In: Proceedings of the National Conference on Women and HIV, Pasadena, CA, 4-7 May 1997:152. Google Scholar 38. Pregnancy outcomes following systemic prenatal acyclovir exposure-June 1, 1984-June 30, 1993. MMWR Morb Mortal Wkly Rep. 1993; 42:806-9. Google Scholar 39. O'Sullivan M, Boyer P, Scott G, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group Study (protocol 082). Am J Obstet Gynecol. 1993; 168:1510-6. Google Scholar 40. Moodley J, Moodley D, Pillay K, et al. Antiviral effect of lamivudine alone and in combination with zidovudine in HIV-infected pregnant women [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, 22-26 January 1997:176. Google Scholar 41. Sandberg J, Slikker W. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides. FASEB J. 1995; 9:1157-63. Google Scholar 42. FDA Public Health Advisory. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). JAMA. 1997; 278:379. Google Scholar 43. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant females infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-2). Google Scholar 44. Sperling R, Shapiro D, Coombs R, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus from mother to infant. N Engl J Med. 1996; 335:1621-9. Google Scholar 45. Eastman P, Shapiro D, Coombs R, et al. Maternal genotypic ZDV resistance and failure of ZDV therapy to prevent mother-child transmission [Abstract]. In: Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, 22-26 January 1997:160. Google Scholar Author, Article, and Disclosure InformationAffiliations: Previousarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntiretroviral Therapy: Time To Think StrategicallyOren J. Cohen, MD June 15, 1998Volume 128, Issue 12_Part_2Page: 1079-1100KeywordsAIDSAdolescentsAdverse reactionsAntiretroviral therapyAntiretroviralsBlood plasmaClinical trialsDrug interactionsDrug therapyDrugsHIVHIV infectionsHealth careHealth care providersInfantsOpportunistic infectionsToxicityViral loadViral replicationViremia ePublished: 15 June 1998 Issue Published: June 15, 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...